 - Patients who were newly diagnosed as chronic phase chronic myelogenous leukemia, agree with the participation to IDEAL study A Phase IV Study to Evaluate Efficacy and Safety of ImatinibGlinib 600mgday Depending on Early Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722 after informed consent, but were excluded finally from the IDEAL study 